Background:Accuratemeasurementofoutcomesisessentialtomonitortheeffectivenessofpublichealthpolicies.InItaly,theMinistryofHealthhaschosen30-daymortalityaftermajorsurgicalormedicalproceduresas themainoutcomemeasure,poolingallpulmonaryresectionsformalignancyinasinglecategory.Thepresent auditevaluatedallpulmonaryresectionsperformedovera13-yearperiodinasingleinstitutiontoassesstheimmediate(30-daymortality)andlong-term(5-yearsurvival)outcomesaccordingtotypeandstageofdiseaseand extentofsurgery. Methods:Weanalyzedtheresultsof4,234firstpulmonaryresectionsperformedfrom2003to2015forlung cancer (2,636), lung metastases (1,080), other primary cancers (259) and benign diseases (259). The median follow-upofcancerpatientswas4.1years. Results:Overall30-daymortalitywas1.1%,being1.2%forlungcancer,0.3%forlungmetastases,3.5%forpneu-monectomies,1%forlobectomies,and0.5%forsublobarresections.Amonglungcancerpatients,30-daymortalitywas0.7%forsimpleanatomicalresections,2.8%forcomplexresections,0.7%forstageI,and1.6%forhigher stages. Overall 5-year survival was 56% for lung cancer, 49% for lung metastases, and 53% for other primary cancers(p=0.03).Accordingtothesurgicalprocedureforlungcancer,5-yearsurvivalwas60%,55%and36%for lobectomies,segmentectomiesandpneumonectomies,respectively(p<0.0001).
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effectiveness of public health policies and to assess the efficiency of intervention, including cost/benefit evaluations,inordertohelpstakeholdersoptimizetheuseoflimitedfinancialresourcesandaddressresearchinvestments. Theavailabilityofanindependentsourceofreliableinformationabouttheperformanceofcurrenttherapiesisfundamentalalsoforincreasingpatients'awarenessoftherapeutic strategies.
In the USA, typical examples of public data on medical outcomes are the Surveillance, Epidemiology and End Results(SEER)andMedicaredatabasepublications (1) .Inthe last3decades,SEERaswellastheSocietyofThoracicSurgeons(STS)reportsonthoracicsurgeryclearlydemonstrated thatahigherlevelofquality,betteradherencetoguidelines, andalargernumberofproceduresperyearbyinstitutionare Thirty-day mortality and five-year survival in thoracic surgery: "real-world" assessment of outcomes from a single-institution audit
Introduction
Inmodernmedicine,accuratemeasurementsofimmediate and long-term outcomes are crucial to monitor the associatedwithlowerimmediatemortalityandbetterlongtermsurvival (2) (3) (4) (5) (6) (7) .
Similarly,inEurope,theUnitedKingdom'ssecondNational Thoracic Surgery and Outcomes Report (8) and France's National Cancer Plan based on the Epithor National Database(9)haveprovidedlarge-scalestatisticsonthoracicsurgeryoutcomes,including30-daymortalitybyprocedure.In addition,theEuropeanSocietyofThoracicSurgeons(ESTS) hasdesignedadatabasetoprovideatoolforafairevaluationofperformanceacrossdifferentEuropeanthoracicsurgeryunits (10) .Furthermore,theESTSupdatedrisk-adjusted modelsofmorbidityandmortalityinordertoprovideeasier instruments of risk assessment for thoracic surgery institutions (11, 12) .
In Italy, an official agency of the Ministry of Health, the Agenzia Nazionale per i Servizi Sanitari Regionali (AGENAS), provided 30-day mortality statistics after major surgical or medicalproceduresforeachItalianhospitaloveraperiodof 6years(2008-2013)basedonadministrativedatasuchasdischarge summaries and diagnosis-related groups (13) . Given thesourceofthemedicaldata,theAGENASreportsonthoracicsurgerycombineallpulmonaryresectionsformalignant tumorswithoutdistinctionofthetypeofdisease(primarylung cancer,lungmetastases,othermalignancies),extentofresection(wholelung,lobe,lesservolume),andcomplexityofthe procedure(lungonly,nodaldissection,extensiontoadjacent structures,organreplacementorreconstruction).Noreports onlong-termoutcomesarereleasedforthesamepopulations.
Thepresentauditanalyzedallpulmonaryresectionsperformed at the Istituto Nazionale dei Tumori of Milan (INTM) overa13-yearperiodwiththeaimofassessingthe immediate andlong-termoutcomes(30-daymortalityand5-yearsurvival) ofsurgicalproceduresaccordingtothetypeofdiseaseandextentofsurgicalresection.
Methods
Thecurrentstudyincludedallsurgicalprocedurescarried outatINTMfromJanuary1,2003toDecember31,2015.All resectionsinpediatricpatients(below18yearsofage)were excluded from thecohort. Resections wereperformed by a variety of operative procedures classified as anatomical resections (pneumonectomy, lobectomy, segmentectomy) or non-anatomical sublobar resections, including wedge and precisionresections.Inaddition,theproceduresperformed wereclassifiedassimple(i.e.,notassociatedwithotherresections) or complex (associated with resections of adjacent structures, organ replacement or reconstruction). For patientswithprimarylungcancer,simpleanatomicalresectionsalwaysincludedsystematicdissectionofmultiplehilar and mediastinal lymph-node stations. All anatomical resections for primary lung cancer were staged according to the 7 th edition of the International Association for the Study of LungCancer(IASLC)stagingsystem (14) .Allinformationrelating to the period of hospitalization were validated through themedicalrecordregister,particularlyforpatientswhodied duringhospitalization.
Of the 7,602 surgical procedures recorded we included onlythefirstpulmonaryresectionperformedineachindividual,correspondingtoatotalof4,234patients (Fig.1) .Benign diseaseswereanalyzedseparately(SupplementaryTableS1-Thirty-daymortalityandpostoperativehospitalstayinpatients withbenigndiseases.Availableonlineatwww.tumorijournal. com).Twooutcomes(proportionofpatientswhoexperienced 
Results
Of the 7,602 thoracic surgical procedures recorded at INTM from January 2003 to December 2015, 4,857 (64%) werepulmonaryresectionsand4,234(87%)representedthe first surgical procedure (Fig. 1) . The remaining 623 subsequentlungresectionswerenotincludedintheanalysis.
The patients' characteristics are illustrated in Table I . Out of 4,234 first pulmonary resections, 259 (6.1%) were performed for benign diseases. Among the 3,975 patients (93.9%) with malignant tumors, 2,636 (66.3%) had primary lungcancer,1,080(27.2%)lungmetastases,and259(6.5%) other primary malignancies. The most common resection performedwaslobectomy(51%),followedbywedgeorprecisionsublobarresections(30%),anatomicalsegmentectomies (9.8%),andpneumonectomies(9.2%). Table II shows the 30-day mortality in patients with malignant tumors according to cancer type and resection volume.Patientswithotherprimarymalignancies(thymoma,sarcomaorgerm-celltumors)hadthehighestmortality(3.1%)whilethosewithlungmetastaseshadthe lowest mortality (0.3%), independent of the resection volume. Pneumonectomywasassociatedwithasignificantlyhigher mortalityrate(3.5%)thanlobectomy(1%),segmentectomy (0.5%) or wedge/precision resection (0.5%), regardless of thetypeofdisease.Inlungcancerpatients,30-daymortality (1.2%overall)variedaccordingtotheresectionvolumeand complexityofthesurgicalprocedure(Tab.II),beinghigher forpneumonectomies(3.1%)versuslobectomies(1.1%)or sublobarresections(0.6%combiningsegmentsandwedg-es),withamajorimpactofcomplexresectionscomparedto simple procedures (2.8% vs. 0.7% overall), which was evidentforpneumonectomy(3.8%vs.2.0%),lobectomy(2.5% vs.0.7%)andsublobarresections(2.6%vs.0.4%).TableII also shows the 30-day mortality according to pathological tumor stage in 2,376 lung cancer patients undergoing anatomical resections. Stage I lung cancer had a significantlylowermortalitythan higherstages(0.7%vs. 1.6%), and the effect was evident in the largest group of 1,845 lobectomies(0.7%vs.1.3%)aswellasinpneumonectomies (0%vs.3.6%).
Thirty-day mortality
Comparedtocancerpatients,postoperativemortalitywas lowerbutnotabsent(0.4%)inlungresectionsforbenigndisease(SupplementaryTableS1).The95%CIsof30-day mortality were0.8-1.4overall,0.8-1.7forprimarylungcancer,0.7-1.6for lobectomies,and2.1-5.9forpneumonectomies. Missing data are hidden.
In summary, the highest mortality was observed in patients undergoing pneumonectomy, but the type of malignancy,thecomplexityofresection,andthepathologicalstage oflungcancerplayedasignificantrole.Inparticular,complex resectionsshowedahighermortalityratethansimpleresectionsregardlessoftheresectedlungvolume.
Overall,themedianpostoperativehospitalstaywas6days (Tab. III), being longer for primary tumors other than lung cancer (9 days) and pneumonectomies (8 days), and shorter for lung metastases and wedge and precision resections (5days).
Overall survival
Sixpatients(0.1%)wereexcludedfromthesurvivalanalysisduetomissingfollow-up.Overall,16,309.62person-years were accumulated by patients with malignant tumors and 1,870 deaths occurred during the follow-up period, with a mortality rate for all causes of 11.5/100 person-years. The 5-yearsurvivalaccordingtocancertypeshowedasignificant differencebetweenpatientswithlungcancer,otherprimary malignancies, and lung metastases, with a cumulative survival of 56%, 53%, and 49%, respectively (p = 0.03; Fig. 2 ). Comparedwithprimarylungcancerpatients,thosewithlung metastases and other malignancies had an adjusted hazard ratio(HR)of1.21(95%CI1.08-1.36)and1.26(1.03-1.54),respectively(Tab.IV).Whentheanalysiswasrestrictedtolung cancer patients and anatomical resections, 5-year survival waslowerinpatientsundergoingpneumonectomycompared withlobectomyandsegmentectomy;thedifferencewasstatisticallysignificant(36%vs.60%and55%,p<0.0001; Fig.3) . Patients who underwent pneumonectomies had worse survivalcomparedwithallotherresectiontypes(HR1.91;95% CI1.49-2.46;Tab.IV).Also,asignificantoutcome stratification wasevidencedbycombiningcomplexityofthesurgicalprocedureandlungresectionvolume(p<0.0001; Fig.4) ,withan HRof1.96 forsimple pneumonectomies and 2.59forcom-plexones(Tab.IV). Finally, 5-year survival by pathological tumor stage confirmed the expected outcome according to the new TNM stagingsystem:73%forstageI,55%forstageII,and36%for stageIII-IV(p<0.0001; Fig.5 ),andpatientswithpathological stageIIorIIIhadanincreasedriskoflong-termmortalitycomparedtostageIpatients(HR2.1,95%CI1.40-3.15andHR3.4, 95%CI2.35-4.99,respectively;Tab.IV).Interestingly,asimilar impact of pTNM on 5-year survival was observed when restrictingtheanalysistothe580patientstreatedbycomplex resectionsonly(72%vs.49%and29%,respectively,p<0.000; HR2.1and3.43;Tab.IVandSupplementaryFig.S1-Five-year lung cancer survival of anatomical resections according to pathologicalstageinpatientswithcomplexresections.Available online at www.tumorijournal.com). The independent predictive value of anatomical resection volume and pTNM wasmaintainedaftermultipleadjustmentforage,sex,anatomicalresectionandpTNM,withanHRof1.54forpneumo-nectomyand3.37forstageIII-IV(SupplementaryTableS2).
Discussion
Real-world medicine, as opposed to evidence-based medicinegeneratedbyprospectiverandomizedtrials,mainly referstotheretrospectiveevaluationoflargeunselectedseries of patients, including all those treated in one or more hospitals,whoseclinicalresultscannotbeaffectedbytheselectionbiasesthataretypicalintheprocessoftrialaccrual. Real-worldevidenceprovidesacomplementaryoverview(or confirmation)oftheresultsthatcanbeachievedinthelarge majorityof"real"patientsroutinelytreatedinclinicalpractice, including elderly and frail patients with comorbidities, whoareusuallyexcludedfromrandomizedtrials (15) .Inthe settingofthoracicsurgery,large-scalemulticenterdatabases havebeenemployedbothintheUSA(SEER,STS)andEurope (ESTS) in an effort to provide reliable short-and long-term outcomeresultsandeasy-to-usequalityindicatorsofinstitutionalperformance (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) .
Ontheotherhand,majorsingleinstitutionscanusethe auditinstrumenttoanalyzetheirownsurgicaldatabasesand provide updated outcome indicators to be shared with patients. In order to avoid retrospective clinical selection and potential biases, an institutional audit should identify all treatedpatientswithinagivenperiodthroughindependent medicalandadministrativedatabases,regardlessoftheirprivate or public status, with formal checking by institutional authorities.Forthepresentaudit,wemergedalltheexisting databasesatINTM,fromtheICT,clinicaladministration,pathology,surgery,andanesthesiologydepartments,toretrieve eachandeverypatient,includingthoseadmittedtomedical orprivatewardsandintensivecareunits.
Eventhough30-daymortalityisonlyonemeasureofthe overall health-care quality (11), our outcome analysis was basedonall-causemortality,whichrepresentsthemostsolid endpoint for this type of institutional audit. In contrast with themajorityofsurgicalseries,wherefollow-upwasobtained through the outpatient clinic or telephone calls to patients' families,weusedsystematicrecordlinkagewiththevitalstatus NationalRegistryOfficedatabase,whichisregularlyupdated within6monthsofdeath,andinourcohortguaranteeda99% long-termfollow-up.Otherrelevantendpointssuchastumor relapse, new primary cancer, adjuvant or salvage treatment areverydifficulttoaccuratelyidentifyinalarge-scalesurgical auditandarebeyondthescopeofthepresentexercise.
Weareawarethattheadjustmentforageandsex,anatomical resection and pTNM stage but not other important riskmodifierssuchasconcurrentchronicdiseases,cardiopulmonary function and medical comorbidity is a limitation of thepresentaudit (16, 17) ,butthesedatawerenotavailable for a significant proportion of patients. It is our intention, however, to provide in the near future additional outcome analysesofthelungcancercohort,adjustedforchronicobstructivepulmonarydisease,priorcardiacmorbidity,pulmonaryfunction,andothermedicalcomorbidities.
In general terms, our results confirm that overall 30-day mortalityinthoracicsurgeryhasdeclinedinthelast20years (Tab.V),buttherearestillsignificantvariationsamongdifferent series,eveninthelastdecade.Infact,the1.3%valueobserved in our series for major lung cancer resections (lobectomy or pneumonectomy)issimilartothemostrecentSTSoutcomes (0.9%-1.8%)(6)butmuchlowerthanthe2.7%reportedbyESTS (18) ,the3.7%ofSEER-Medicare(1),andthe7.4%of Epithor (9) . Eventhoughthesizedifferencebetweensingle-institutionand population-based series is substantial, our 95% CIs of 30-day mortalityconfirmthefavorabletrend(Tab.IV).
InthespecificItalianscenario,ouroverall30-daymortality for malignant disease (1.1%) is in line with the average Afurtherelementtobeconsideredasamarkerofpotentiallyunnecessarysurgeryisthefrequencyoflungresections forbenigndiseases.Inthepresentseries,only6%ofpatients underwent pulmonary resection without a final pathologicaldiagnosisofmalignancy.Thisvalueiswellbelowthe10% thresholdconsideredadequatebyinternationalthoracicsurgeryguidelines (22) .
Inourview,themostvaluablepieceofinformationprovided by this audit is the correlation between short-term mortality and long-term outcome of surgical resections for thoracic malignancies. In fact, the overall 5-year survival of 56%for2,634lungcancerpatientsand53%for259subjects withotherprimarycancersrepresentsolidproofoflong-term effectiveness.Evenmoreremarkably,1,076patientswithre-sectedlungmetastasesshoweda49%5-yearsurvival,witha substantialprospectofpermanentcureincarefullyselected metastaticdisease,andverylow(0.3%)postoperativemortality.Thesurgicalbenefitratioappearsreasonablealsofor extended operations such as complex pneumonectomies in lungcancerpatients,wherea30-daymortalityof3.8%was compensatedbyanacceptable9-fold5-yearsurvival(35%).
Finally,theobservedlong-termoutcomeprovidesreassuring information on the appropriateness of patient selection aswellasonthequalityofsurgicalmanagement.Infact,the stage-related5-yearsurvivalamonglungcancerpatientswas fullyconsistentwiththenewinternationalTNMfigures (14) . Inparticular,the36%5-yearsurvivalshownin798stageIII-IV patientsmatchesverywellwitha1.6%30-daymortality,and is above the average life expectancy with definitive chemoradiotherapy,andthemostrecentpopulation-basedSEERreportshowinga29%5-yearsurvivalrateforstageII-IIIdisease and5%forstageIV (23) .Thisaudittherebyconfirmsthevalidityofthesurgicalchoiceintermsofthebalancebetweenearly mortalityandlatesurvivalalsoinadvanced-stagelungcancer.
Non-anatomical sublobar resections or lobectomies without hilar and mediastinal lymph node dissection may belinkedtoa0.5%to1%reductionof30-daymortality,but theSEERreportsclearlydemonstratethattheultimatecost of suboptimal surgery for primary lung cancer is a 10% to 20%reductionof5-yearsurvival (2, 4) .Inthepresentseries, lobectomy plus systematic nodal dissection yielded a 60% 5-yearsurvivalrateinlungcancerpatients(allstages)atthe costofa30-daymortalityof1.1%.Forthesereasons,periodic statisticsprovidedbynationalhealthauthoritiessuchasAGENASshouldinclude30-daymortalityofhomogeneousgroups ofpatients(e.g.,lobectomyforprimarylungcancer)aswell asthecorresponding5-yearsurvival.
Conclusion
In conclusion, 30-day mortality in thoracic surgery is significantly associated with the type and stage of disease, lungresectionvolume,andcomplexityofsurgicalprocedure. Postoperative mortality and 5-year survival are 2 complementarymeasuresofperformance,andforbettermonitoring of thoracic surgery outcomes in a real-world setting we suggestevaluatinglungcancerseparatelyfromotherthoracic malignancies,andincluding5-yearsurvivalratesstratifiedby resectionvolumeandsurgicalprocedurecomplexity.
